Concord Biotech Appoints Raviraj Karia as New CFO to Strengthen Financial Leadership

In a strategic move to reinforce its financial leadership, Concord Biotech Ltd has appointed Raviraj Karia as the company’s new Chief Financial Officer (CFO). The appointment reflects Concord Biotech’s continued commitment to strengthening financial discipline and driving sustainable growth as it expands its presence in domestic and global biopharma markets.

Karia, who succeeds the previous finance head, brings a wealth of experience in corporate finance, risk management, and strategic planning. His appointment is expected to support the company’s next phase of operational excellence and value creation.

Key Highlights

New CFO: Raviraj Karia joins as Chief Financial Officer, effective December 18, 2025.

Strategic Focus: To enhance financial strategy, risk management, and growth planning.

Industry Experience: Karia has served in senior finance roles across reputed organizations.

Company Outlook: Concord Biotech continues to strengthen its leadership team to sustain innovation-driven growth.

Source: BSE Corporate Filings, Exchange Announcement.